Growth hormone

CJC-1295

Long-acting GHRH analog (with or without DAC)

CJC-1295 is a modified version of growth hormone-releasing hormone designed to last longer in the body. It was never approved by the FDA, and federal advisers have voted against allowing pharmacies to compound it.

Key facts

  • Commonly discussed for: raising growth hormone and IGF-1.
  • Evidence (C): The main human data are two small randomized, placebo-controlled trials in healthy adults (published 2006) that measured hormone levels, not health outcomes. No efficacy trials for a medical condition have been published.
  • FDA status: Not recommended. On December 4, 2024 the PCAC voted 0-13 against adding CJC-1295 (free base) to the 503A Bulks List, agreeing with FDA, and the related salt forms were also rejected.
  • Legitimate access: No clear legal route yet.
  • Last reviewed: October 1, 2026.

Read the deep dives

Sources